Want to join the conversation?
In March, $REGN reported positive data from the Phase III Odyssey Escape study in patients with heterozygous familial hypercholesterolemia. Earlier this week, for Fasinumab, its NGF antibody, $REGN announced positive data from its Phase II/III study in osteoarthritis.
$MON shares dip slightly; I wonder this is because of the environmental lawsuit filed by the Washington state against the production of PCBs.
My bet is that $FR will reach $32 in the short term. It’s time it broke the 52-week high and had its fair share of growth.
$WYNN got bruised up by China after its decision to cut withdrawal limit in Macau ATMs. Wynn Resorts shares went down by more than 11%! Well who could have guessed that right?